EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ — Cambrex, a world-leading contract development and manufacturing organization (CDMO) providing drug substance, pharmaceutical and analytical services throughout the entire cycle of Drugs, today announced that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharmaceutical customers.
Snapdragon specializes in continuous flow and batch process development for Active Pharmaceutical Ingredients (APIs), using cutting-edge automation technology and proprietary equipment to solve complex analytical and process development challenges. The team of scientists and engineers apply in-depth process knowledge from data-rich experimentation to rapidly design and execute efficient GMP and non-GMP manufacturing processes. Headquartered for R&D and manufacturing in Waltham, Massachusetts, Snapdragon’s 74 employees have strong ties to the local scientific community, with 31 Ph.D. scientists on staff.
“The acquisition of Snapdragon will accelerate our growth in the area of continuous flow process development and manufacturing, complementing our recent organic investments in our High Point, North Carolina facility,” said Tom Loewald, Cambrex CEO. “With R&D and manufacturing capabilities in the heart of the Boston Biopharmaceutical Center, Snapdragon will continue to focus on solving its customers’ toughest process development challenges.”
“We are very pleased to join Cambrex, a company with more than 40 years of experience in drug development and manufacturing,” said Matt Bio, CEO of Snapdragon. Partnering our best-in-class process development capabilities with Cambrex’s larger-scale manufacturing facilities in North America and Europe is a natural fit for both our employees and our customers.”
Snapdragon recently opened its second facility, a new 51,000-square-foot facility to manufacture experimental pharmaceuticals for human clinical trials. The new facility expanded the company’s ability to supply clinical intermediates and drug substances.
The transaction is expected to close upon completion of the usual regulatory approvals. This will be Cambrex’s second acquisition in a year along with Q1 Scientific, in line with its strategy to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing.
About CambrexCambrex is a world-leading contract development and manufacturing organization (CDMO) providing drug substance, drug product and analytics services throughout the drug life cycle. With more than 40 years of experience and a growing team of more than 2,300 experts serving global customers in North America and Europe, Cambrex is a trusted partner in the brand and generic markets for the development and manufacturing of APIs and forms. finished pharmaceuticals.
Cambrex offers a range of specialized pharmaceutical substance technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid state science, materials characterization, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including solids, semi-solids, and oral liquids, and has the expertise to manufacture specialized dosage forms such as modified-release, fixed-dose combination, pediatric, bilayer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.
logo – link
View original content: enlace
